Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Breast Neoplasms 3Gastroesophageal Reflux 2Zollinger-Ellison Syndrome 1Xerostomia 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Stomach Neoplasms 1Pseudomyxoma Peritonei 1Oropharyngeal Neoplasms 1Multiple Endocrine Neoplasia 1Mucositis 1Lymphoma, B-Cell, Marginal Zone 1Leukemia, B-Cell 1Helicobacter Infections 1Heartburn 1Head and Neck Neoplasms 1Gastritis, Atrophic 1Endometrial Neoplasms 1Carcinoma, Neuroendocrine 1Carcinoid Tumor 1Barrett Esophagus 1Appendiceal Neoplasms 1

Interventions

gallium Ga 68 dotatate 5Everolimus 5lanreotide 3cabozantinib 3Nivolumab 3pasireotide 2lutetium Lu 177 dotatate 2Temozolomide 2Sunitinib 2Octreotide 2Ga(III)-DOTATOC 2Erlotinib Hydrochloride 2Capecitabine 2zimberelimab 1veliparib 1telotristat ethyl 1recombinant interferon alpha 2b-like protein 1pertuzumab 1nintedanib 1ibrutinib 1ganitumab 1fluorodopa F 18 1carfilzomib 1aflibercept 1Sorafenib 1Somatostatin 1Serotonin 1Ramucirumab 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoid Tumor × Lansoprazole × Clear all
NCT01216267 2013-01-16

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

University of Western Ontario, Canada

Phase NA Completed
200 enrolled
Endocrine

Carcinoid Tumor, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡